Teniposide
Overview
Teniposide is a cancer medication. Teniposide interferes with the growth of cancer cells and slows their growth and spread in the body.It is in a class of drugs known as podophyllotoxin derivatives.
Categories
- 8 Antineoplastics, immunomodulators and drugs used in palliative care
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Teniposide's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 50 to 165 mg/m2 | 110 (107.5) | 24 hourly | IV | Initially for 5 days then twice weekly as a 30-60 minutes infusion solution of upto 1mg/ml in NaCl 0.9% or D5W. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Teniposide is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Teniposide is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Teniposide
Back to top
Previous Drug Generic - Next Drug Generic